AnalystBook Research · Company Intelligence

Centurion Acquisition Corp.

ALFNasdaq

Built from Centurion Acquisition Corp.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Centurion Acquisition is a SPAC with no revenue, positive net income from non-core sources, and negative equity.

The read at a glance✓ Audited against SEC data
  • Business mixBlank-check company seeking a targetWatch
  • RevenueNo revenue in local rowsNote
  • ProfitabilityNet income was $11.7MNote
  • CashCash from ops was -$0.6MWatch
  • Balance sheetEquity was -$13.6MWatch
  • Insiders0 buys / 0 sellsNote
  • AccountingNo forensic screen in bundleNote

Business

Centurion Acquisition is a Cayman Islands blank-check company formed in January 2024 to pursue a merger, amalgamation, share exchange, asset acquisition, share purchase, or similar business combination.

Leadership changes

From Centurion Acquisition Corp.'s own filings, the day they're filed.

  • Thomas Vu · director · appointmenteff. 2025-06-09
  • Mark Gerhard · directors · appointmenteff. 2024-06-12
  • Riaan Hodgson · directors · appointmenteff. 2024-06-12

Latest filings

  • 10-Q · Quarterly report2026-08-14
  • 8-K · Company announcement2026-06-16
  • 8-K · Company announcement2026-06-12
  • 8-K · Company announcement2026-06-05
  • DEF 14A · Annual proxy (pay & governance)2026-05-21
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Centurion Acquisition Corp., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.